

Effect of non-specific reversal agents on anticoagulant a rivaroxaban

Thrombosis and Haemostasis

108, 217-224

DOI: 10.1160/th12-03-0179

Citation Report

#	ARTICLE	IF	CITATIONS
2	Approaches to Diagnosing and Managing Anticoagulant-Related Bleeding. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 702-710.	1.5	14
3	Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1841-1848.	1.9	164
4	Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. <i>Lancet Neurology</i> , The, 2012, 11, 1066-1081.	4.9	75
5	Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. <i>Thrombosis and Haemostasis</i> , 2012, 108, 876-886.	1.8	155
7	Management of Atrial Fibrillation: Direct Factor IIa and Xa Inhibitors or –Warfarin Shotgun?. <i>Mount Sinai Journal of Medicine</i> , 2012, 79, 705-720.	1.9	1
8	Antithrombotic agents and invasive procedures - Hematologist point of view. <i>Thrombosis Research</i> , 2012, 130, S61-S62.	0.8	2
9	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2012, 14, 1385-1413.	0.7	2,319
11	Management of Bleeding in Patients Receiving Conventional or New Anticoagulants. <i>Drugs</i> , 2012, 72, 1965-1975.	4.9	11
13	Current Trial-Associated Outcomes With Warfarin in Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2012, 172, 623.	4.3	139
14	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	1.0	3,144
15	Surgery and invasive procedures in patients on long term treatment with oral direct thrombin or factor Xa inhibitors (update 2012). <i>Sang Thrombose Vaisseaux</i> , 2012, 24, 269-278.	0.1	2
16	Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2012, 108, 201-202.	1.8	13
17	Pro: –Antidote for new anticoagulants– Specific target of inhibition requires a specific target for neutralisation. <i>Thrombosis and Haemostasis</i> , 2012, 108, 621-622.	1.8	5
18	Bleeding and antidotes in new oral anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 191-202.	0.7	84
19	Reversal of target-specific oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 195-202.	1.0	36
20	Dabigatran Excess: Case Report and Review of the Literature. <i>Cardiology and Therapy</i> , 2013, 2, 111-124.	1.1	8
21	Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 83-97.	0.6	133
22	Established and new-generation antithrombotic drugs in patients with cirrhosis – Possibilities and caveats. <i>Journal of Hepatology</i> , 2013, 59, 358-366.	1.8	107

#	ARTICLE	IF	CITATIONS
23	A systematic update on the state of novel anticoagulants and a primer on reversal and bridging. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2013, 1, 418-426.	0.9	7
24	Case scenario "Thoracic trauma. <i>Annales Francaises D'Anesthesie Et De Reanimation</i> , 2013, 32, 504-509.	1.4	4
25	Novel thrombin and factor Xa inhibitors. <i>Current Opinion in Hematology</i> , 2013, 20, 552-557.	1.2	15
26	Darexaban: Anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa. <i>Thrombosis Research</i> , 2013, 131, 450-456.	0.8	3
27	Assessment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013, 29, S34-S44.	0.8	40
28	Periprocedural Management of Oral Anticoagulation in Patients With Atrial Fibrillation: Approach in the Era of New Oral Anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013, 29, S54-S59.	0.8	15
29	Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. <i>International Journal of Cardiology</i> , 2013, 168, 4228-4233.	0.8	96
31	Reversal of Novel Anticoagulants: Role of Clotting Factors and Complex Concentrates. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 200-207.	0.6	0
32	Management of bleeding and coagulopathy following major trauma: an updated European guideline. <i>Critical Care</i> , 2013, 17, R76.	2.5	780
33	Practical management of new oral anticoagulants after total hip or total knee arthroplasty. <i>Musculoskeletal Surgery</i> , 2013, 97, 189-197.	0.7	11
35	Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) " March 2013. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 382-393.	0.7	281
38	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1029-1049.	0.6	4
39	Management of bleeding and reversal strategies for oral anticoagulants: Clinical practice considerations. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1914-1929.	0.5	49
40	Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. <i>Critical Care</i> , 2013, 17, 230.	2.5	46
41	Pharmacologic interventions for reversing the effects of oral anticoagulants. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, S12-S21.	0.5	42
42	New Avenues for Anticoagulation in Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 68-77.	2.3	21
43	Acute management of bleeding in patients on novel oral anticoagulants. <i>European Heart Journal</i> , 2013, 34, 489-498.	1.0	152
45	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2013, 15, 625-651.	0.7	721

#	ARTICLE	IF	CITATIONS
47	Gestion p�ri-op�ratoire des nouveaux anticoagulants oraux (NACOs). Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2013, 2013, 7-12.	0.0	2
48	Actualizaci�n detallada de las gu�as de la ESC para el manejo de la fibrilaci�n auricular de 2012. Revista Espanola De Cardiologia, 2013, 66, 54.e1-54.e24.	0.6	14
49	Rivaroxaban: An Oral Factor Xa Inhibitor. Clinical Therapeutics, 2013, 35, 4-27.	1.1	27
50	Anticoagulation in heart failure: current status and future direction. Heart Failure Reviews, 2013, 18, 797-813.	1.7	28
51	Clinical management of rivaroxaban-treated patients. Expert Opinion on Pharmacotherapy, 2013, 14, 655-667.	0.9	19
52	Management of bleeding in patients taking <sc>FX</sc> and <sc>FII</sc> inhibitors. British Journal of Haematology, 2013, 160, 1-2.	1.2	6
53	Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Review of Cardiovascular Therapy, 2013, 11, 129-141.	0.6	36
54	Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients. Expert Opinion on Emerging Drugs, 2013, 18, 9-23.	1.0	16
55	Reversal of Oral Anticoagulation. Pharmacotherapy, 2013, 33, 1199-1213.	1.2	21
56	In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. Journal of Thrombosis and Haemostasis, 2013, 11, 1111-1118.	1.9	73
57	Improving the use of direct oral anticoagulants in atrial fibrillation. European Journal of Internal Medicine, 2013, 24, 288-294.	1.0	11
58	Reversal of novel oral anticoagulants in patients with major bleeding. Journal of Thrombosis and Thrombolysis, 2013, 35, 391-398.	1.0	78
59	Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thrombosis and Haemostasis, 2013, 110, 162-172.	1.8	131
60	Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation. American Journal of Kidney Diseases, 2013, 62, 615-632.	2.1	69
61	Dabigatran: Is There a Role for Coagulation Assays in Guiding Therapy?. Annals of Pharmacotherapy, 2013, 47, 828-840.	0.9	8
62	Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors. Annals of Pharmacotherapy, 2013, 47, 841-855.	0.9	27
63	Rivaroxaban: Practical Considerations for Ensuring Safety and Efficacy. Pharmacotherapy, 2013, 33, 1223-1245.	1.2	18
64	Treatment of Bleeding Complications When Using Oral Anticoagulants for Prevention of Strokes. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 288-298.	0.4	24

#	ARTICLE	IF	CITATIONS
65	Update on Heart Failure, Heart Transplant, Congenital Heart Disease, and Clinical Cardiology. Revista Espanola De Cardiologia (English Ed), 2013, 66, 290-297.	0.4	2
66	The role of the laboratory in treatment with new oral anticoagulants. Journal of Thrombosis and Haemostasis, 2013, 11, 122-128.	1.9	69
67	Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban. Canadian Journal of Cardiology, 2013, 29, S24-S33.	0.8	162
68	Developing a management plan for oral anticoagulant reversal. American Journal of Health-System Pharmacy, 2013, 70, S21-S31.	0.5	19
69	Stroke prevention in patients with atrial fibrillation - anticoagulation strategy 2012. Cor Et Vasa, 2013, 55, e95-e100.	0.1	0
70	Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. Journal of Thrombosis and Haemostasis, 2013, 11, 615-626.	1.9	28
71	Challenges in the management of acute peptic ulcer bleeding. Lancet, The, 2013, 381, 2033-2043.	6.3	178
72	Oral anticoagulants in the management of venous thromboembolism. Nature Reviews Cardiology, 2013, 10, 397-409.	6.1	14
73	Rivaroxaban: A Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation. Drugs, 2013, 73, 715-739.	4.9	14
75	Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey. Europace, 2013, 15, 1526-1532.	0.7	19
76	Management of New Anticoagulants in the ICU. ICU Director, 2013, 4, 326-331.	0.2	0
77	The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders. Hematology American Society of Hematology Education Program, 2013, 2013, 44-51.	0.9	15
78	Reversing the action of newer oral anticoagulants. American Journal of Health-System Pharmacy, 2013, 70, 16-17.	0.5	0
80	Novel Oral Anticoagulants: A Review of the Literature and Considerations in Special Clinical Situations. Hospital Practice (1995), 2013, 41, 8-18.	0.5	3
81	Prothrombin Complex Concentrate. Hospital Pharmacy, 2013, 48, 951-957.	0.4	11
82	Practical management of patients on apixaban: a consensus guide. Thrombosis Journal, 2013, 11, 27.	0.9	30
83	Evaluation of Bleeding Rates in Renal Transplant Patients on Therapeutic Intravenous Heparin. Hospital Pharmacy, 2013, 48, 936-957.	0.4	4
84	Reversing the action of newer oral anticoagulants. American Journal of Health-System Pharmacy, 2013, 70, 14-16.	0.5	0

#	ARTICLE	IF	CITATIONS
85	Management of Hemorrhage Complicated by Novel Oral Anticoagulants in the Emergency Department. American Journal of Therapeutics, 2013, 20, 300-306.	0.5	18
86	Treatment with novel oral anticoagulants. Current Opinion in Hematology, 2013, 20, 430-436.	1.2	27
87	II. On the reversal of new oral anti-coagulants: can we simply extrapolate data from the animal models to humans?. British Journal of Anaesthesia, 2013, 110, 329-332.	1.5	11
88	Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients. American Journal of Clinical Pathology, 2013, 140, 610-622.	0.4	18
89	Perioperative coagulation management in the intensive care unit. Current Opinion in Anaesthesiology, 2013, 26, 65-70.	0.9	11
90	Laboratory Assessment of Novel Oral Anticoagulants: Method Suitability and Variability between Coagulation Laboratories. Clinical Chemistry, 2013, 59, 807-814.	1.5	86
91	Prophylaxis and treatment of venous thromboembolism in the critically ill. International Journal of Critical Illness and Injury Science, 2013, 3, 143.	0.2	16
92	New oral anticoagulants: An emergency department overview. EMA - Emergency Medicine Australasia, 2013, 25, 503-514.	0.5	3
93	EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. European Heart Journal, 2013, 34, 2094-2106.	1.0	356
94	Dabigatran and Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1591-1597.	2.2	32
95	The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Review of Hematology, 2013, 6, 677-695.	1.0	36
96	Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. Anesthesiology, 2013, 118, 1466-1474.	1.3	158
97	Dabigatran and Bleeding: Still an Emergent Situation?. American Journal of the Medical Sciences, 2013, 346, 259.	0.4	2
98	New oral anticoagulant drugs: real-world data. Personalized Medicine, 2013, 10, 419-422.	0.8	3
99	Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity. Critical Care Medicine, 2013, 41, e42-e46.	0.4	92
100	Anticoagulant and antiplatelet medications encountered in emergency surgery patients. Journal of Trauma and Acute Care Surgery, 2013, 75, 475-486.	1.1	36
101	New Oral Anticoagulants in Atrial Fibrillation. , 2013, , .		0
102	Management of Bleeding Complications of Dabigatran. Journal of Hematology & Thromboembolic Diseases, 2013, 02, .	0.1	1

#	ARTICLE	IF	CITATIONS
103	Dabigatran elimination: is haemodialysis effective?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 580-581.	1.8	3
104	The practical management of bleedings during treatment with direct oral anticoagulants: the emergency reversal therapy. <i>Italian Journal of Medicine</i> , 2013, 7, 48.	0.2	2
105	Reversal of a Dabigatran Overdose: What Are Possible Options?. <i>American Journal of the Medical Sciences</i> , 2013, 346, 259.	0.4	4
106	New Oral Anticoagulants in the Treatment of Pulmonary Embolism: Efficacy, Bleeding Risk, and Monitoring. <i>Thrombosis</i> , 2013, 2013, 1-11.	1.4	14
107	Tutorial in Oral antithrombotic therapy: Biology and dental implications. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2013, 18, e461-e472.	0.7	25
108	New oral anticoagulants: key messages for clinicians. <i>Italian Journal of Medicine</i> , 2013, 7, 74.	0.2	0
109	Dental Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants. <i>Arrhythmia and Electrophysiology Review</i> , 2014, 3, 85.	1.3	4
110	Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. <i>Vascular Health and Risk Management</i> , 2014, 10, 101.	1.0	21
111	Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. <i>Vascular Health and Risk Management</i> , 2014, 10, 291.	1.0	1
112	Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2014, 112, 808-816.	1.8	39
113	Comparative Evaluation of Direct Thrombin and Factor Xa Inhibitors with Antiplatelet Agents under Flow and Static Conditions: An In Vitro Flow Chamber Model. <i>PLoS ONE</i> , 2014, 9, e86491.	1.1	21
114	Management of the Bleeding Patient Receiving New Oral Anticoagulants: A Role for Prothrombin Complex Concentrates. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	35
115	Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?. <i>Thrombosis and Haemostasis</i> , 2014, 112, 189-198.	1.8	92
116	A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution?. <i>Vascular Health and Risk Management</i> , 2014, 10, 507.	1.0	21
117	Management of Severe Dabigatran-Related Hemorrhage: Case Report, Considerations for Management, and Recommendations. <i>Canadian Journal of Hospital Pharmacy</i> , 2014, 67, 43-7.	0.1	5
118	Immediate Treatment of the Anticoagulated Patient with Traumatic Intracranial Hemorrhage. , 2014, , .		0
119	Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: A Sonoclot in vitro study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 591-598.	0.6	10
120	Prolonged Bleeding After Surgery. , 2014, , 151-160.		0

#	ARTICLE	IF	CITATIONS
122	Reversing targeted oral anticoagulants. Hematology American Society of Hematology Education Program, 2014, 2014, 518-523.	0.9	4
123	Perioperative Management of Target-Specific Oral Anticoagulants. Hospital Practice (1995), 2014, 42, 38-45.	0.5	3
124	Strategies for Urgent Reversal of Target-Specific Oral Anticoagulants. Hospital Practice (1995), 2014, 42, 108-125.	0.5	0
126	Direct Oral Anticoagulants. JACC: Cardiovascular Interventions, 2014, 7, 1333-1351.	1.1	81
127	The use of oral anticoagulants for the treatment of venous thromboembolic events in an ED. American Journal of Emergency Medicine, 2014, 32, 1526-1533.	0.7	4
128	Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence. Expert Review of Cardiovascular Therapy, 2014, 12, 933-947.	0.6	6
129	Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation. Clinical Cardiology, 2014, 37, 32-47.	0.7	72
130	Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding. British Journal of Haematology, 2014, 166, 152-153.	1.2	22
131	Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. Journal of Thrombosis and Haemostasis, 2014, 12, 1428-1436.	1.9	181
132	Haemorrhagic stroke due to rivaroxaban and use of prothrombin complex concentrate as a reversal agent. Journal of Pharmacy Practice and Research, 2014, 44, 129-131.	0.5	1
133	Evaluation of Dabigatran Exposures Reported to Poison Control Centers. Annals of Pharmacotherapy, 2014, 48, 354-360.	0.9	15
134	Role of prothrombin complex concentrate in perioperative coagulation therapy. Journal of Intensive Care, 2014, 2, 60.	1.3	49
135	Applying "Patient Blood Management"™ in the trauma center. Current Opinion in Anaesthesiology, 2014, 27, 225-232.	0.9	23
136	"New"™ direct oral anticoagulants in the perioperative setting. Current Opinion in Anaesthesiology, 2014, 27, 409-419.	0.9	44
137	Favorable Outcome After a Subdural Hematoma Treated With Feiba in a 77-Year-Old Patient Treated by Rivaroxaban. Journal of Neurosurgical Anesthesiology, 2014, 26, 183.	0.6	19
138	Emergency surgery and trauma in patients treated with the new oral anticoagulants. Journal of Trauma and Acute Care Surgery, 2014, 77, 486-494.	1.1	14
139	Target-Specific Oral Anticoagulants: Practice Issues for the Clinician. Hospital Practice (1995), 2014, 42, 48-61.	0.5	1
140	Safety of new oral anticoagulant drugs: a perspective. Therapeutic Advances in Drug Safety, 2014, 5, 8-20.	1.0	52

#	ARTICLE	IF	CITATIONS
141	Management of Bleeding Complications. , 2014, , 213-237.		0
142	Rivaroxaban and Hemostasis in Emergency Care. <i>Emergency Medicine International</i> , 2014, 2014, 1-9.	0.3	14
143	Novel Oral Anticoagulants in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 34-44.	1.0	23
146	Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report. <i>Journal of Emergency Medicine</i> , 2014, 46, 525-529.	0.3	25
148	Life-threatening haemorrhagic pericarditis associated with rivaroxaban. <i>International Journal of Cardiology</i> , 2014, 174, e75-e76.	0.8	19
149	The pharmacology of novel oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 217-233.	1.0	54
150	Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 380-391.	1.0	42
151	Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG [®]) to guide decision-making. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 80-83.	1.0	27
152	Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 76-79.	1.0	13
154	Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. <i>Critical Care</i> , 2014, 18, R27.	2.5	89
155	Dabigatran anticoagulation and Stanford type A aortic dissection: lethal coincidence. <i>Acta Anaesthesiologica Scandinavica</i> , 2014, 58, 630-637.	0.7	19
156	Peri-operative management of anticoagulation and antiplatelet therapy in gastrointestinal surgery. <i>Journal of Visceral Surgery</i> , 2014, 151, 125-135.	0.4	3
157	Gestion p [®] riop [®] atoire des nouveaux anticoagulants. <i>Praticien En Anesthesie Reanimation</i> , 2014, 18, 52-59.	0.0	0
158	New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. <i>Acta Anaesthesiologica Scandinavica</i> , 2014, 58, 651-659.	0.7	25
159	Reversal of New, Factor-specific Oral Anticoagulants by rFVIIa, Prothrombin Complex Concentrate and Activated Prothrombin Complex Concentrate: A Review of Animal and Human Studies. <i>Thrombosis Research</i> , 2014, 133, 705-713.	0.8	37
160	Intracranial Hemorrhage and Novel Anticoagulants for Atrial Fibrillation: What Have We Learned?. <i>Current Cardiology Reports</i> , 2014, 16, 480.	1.3	53
161	Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants. <i>American Journal of Emergency Medicine</i> , 2014, 32, 375-382.	0.7	25
162	Toxin-induced Coagulopathy. <i>Emergency Medicine Clinics of North America</i> , 2014, 32, 53-78.	0.5	2

#	ARTICLE	IF	CITATIONS
163	Pharmacological Treatment of Acute Coronary Syndromes. , 2014, , .		2
164	New Oral Anticoagulants and the Cancer Patient. <i>Oncologist</i> , 2014, 19, 82-93.	1.9	180
165	Medicamentos derivados del plasma: fracciones coagulantes y anticoagulantes. <i>EMC - Anestesia-Reanimación</i> , 2014, 40, 1-13.	0.1	0
166	Gestion péri-opératoire des nouveaux anticoagulants oraux. <i>Journal Européen Des Urgences Et De Réanimation</i> , 2014, 26, 173-180.	0.1	0
167	Farmaci derivati dal plasma: frazioni coagulanti e anticoagulanti. <i>EMC - Anestesia-Rianimazione</i> , 2014, 19, 1-11.	0.1	0
168	Management of anticoagulant-related intracranial hemorrhage: an evidence-based review. <i>Critical Care</i> , 2014, 18, 223.	2.5	13
170	New Oral Anticoagulant-Induced Bleeding. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 575-586.	0.7	17
171	Anticoagulation Strategies for the Management of Postoperative Atrial Fibrillation. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 537-561.	0.7	31
172	Treatment of Intracerebral Hemorrhage Associated with New Oral Anticoagulant Use. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 587-594.	0.7	16
173	Perioperative Management of Patients Receiving New Oral Anticoagulants. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 637-654.	0.7	24
174	Ex vivo reversal of the anticoagulant effects of edoxaban. <i>Thrombosis Research</i> , 2014, 134, 909-913.	0.8	43
175	Anticoagulation in atrial fibrillation. <i>BMJ, The</i> , 2014, 348, g2116-g2116.	3.0	68
176	The epidemic of pre-injury oral antiplatelet and anticoagulant use. <i>European Journal of Trauma and Emergency Surgery</i> , 2014, 40, 657-669.	0.8	13
177	Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 247-262.	1.3	5
178	Newer clinically available antithrombotics and their antidotes. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2014, 40, 269-275.	0.6	9
179	Emergency Reversal of Anticoagulation: Novel Agents. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 471.	2.0	13
181	The role of prothrombin complex concentrates in reversal of target specific anticoagulants. <i>Thrombosis Journal</i> , 2014, 12, 8.	0.9	47
182	New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. <i>Internal Medicine Journal</i> , 2014, 44, 525-536.	0.5	129

#	ARTICLE	IF	CITATIONS
183	Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 118-135.	0.7	30
184	Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model. <i>Thrombosis Research</i> , 2014, 134, 729-736.	0.8	28
185	Direct Oral Anticoagulants and Bleeding Risk (in Comparison to Vitamin K Antagonists and Heparins), and the Treatment of Bleeding. <i>Seminars in Hematology</i> , 2014, 51, 102-111.	1.8	17
186	Common Questions in Anticoagulation Management in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 79-86.	0.7	1
187	Recent Advances in Antidotes for Direct Oral Anticoagulants: Their Arrival Is Imminent. <i>Canadian Journal of Cardiology</i> , 2014, 30, 381-384.	0.8	20
188	Acquired Bleeding Disorders. <i>Emergency Medicine Clinics of North America</i> , 2014, 32, 691-713.	0.5	9
189	Reversal of target-specific oral anticoagulants. <i>Drug Discovery Today</i> , 2014, 19, 1465-1470.	3.2	32
190	Potential antidotes for reversal of old and new oral anticoagulants. <i>Thrombosis Research</i> , 2014, 133, S158-S166.	0.8	37
191	New oral anticoagulants—what the cardiothoracic surgeon needs to know. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 1794-1801.e1.	0.4	11
192	Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. <i>Thrombosis Research</i> , 2014, 133, 671-681.	0.8	99
193	Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2014, 112, 989-995.	1.8	97
194	How I treat target-specific oral anticoagulant-associated bleeding. <i>Blood</i> , 2014, 123, 1152-1158.	0.6	108
196	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 117-124.	0.9	50
197	New oral anticoagulants: an approach in older people. <i>Journal of Pharmacy Practice and Research</i> , 2015, 45, 217-225.	0.5	4
198	Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2220-2226.	1.9	26
199	Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review. <i>Clinical Cardiology</i> , 2015, 38, 684-691.	0.7	6
200	Reversal of Rivaroxaban-Induced Alterations on Hemostasis by Different Coagulation Factor Concentrates. <i>Circulation Journal</i> , 2015, 79, 331-338.	0.7	35
201	Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. <i>Thrombosis and Haemostasis</i> , 2015, 113, 728-740.	1.8	95

#	ARTICLE	IF	CITATIONS
202	Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate. <i>Anesthesiology</i> , 2015, 122, 353-362.	1.3	27
203	Management of Bleeding Complications in Patients Taking Direct Oral Anticoagulants at a Large Tertiary Academic Medical Center. <i>Current Emergency and Hospital Medicine Reports</i> , 2015, 3, 162-167.	0.6	0
204	The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban. <i>Critical Pathways in Cardiology</i> , 2015, 14, 53-61.	0.2	15
205	Favorable Outcome of Rivaroxaban-Associated Intracerebral Hemorrhage Reversed by 4-Factor Prothrombin Complex Concentrate. <i>A & A Case Reports</i> , 2015, 4, 151-154.	0.7	9
206	Effective Reversal of Edoxaban-associated Bleeding with Four-factor Prothrombin Complex Concentrate in a Rabbit Model of Acute Hemorrhage. <i>Anesthesiology</i> , 2015, 122, 387-398.	1.3	52
207	Management of Apixaban-Associated Subdural Hematoma. <i>Critical Care Medicine</i> , 2015, 43, e203-e207.	0.4	12
208	Insights into direct anticoagulants. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 492-498.	0.5	1
209	Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. <i>The Cochrane Library</i> , 2018, 2018, CD010555.	1.5	32
211	Non-Vitamin K Antagonist Oral Anticoagulants: The Clinician's New Challenge. <i>Journal of Osteopathic Medicine</i> , 2015, 115, 612-621.	0.4	3
212	Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1162-1163.	1.8	6
213	Novel Oral Anticoagulation Laboratory Monitoring, Interaction and Treatment of Complications. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2015, 15, 115-119.	0.2	0
214	Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors. <i>Hospital Pharmacy</i> , 2015, 50, 569-577.	0.4	3
215	CARDIAC SURGERY New oral anticoagulants – a practical guide. <i>Kardiochirurgia i Torakochirurgia Polska</i> , 2015, 2, 111-118.	0.1	22
216	Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2015, 11, 317.	1.0	11
217	Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0137444.	1.1	46
218	Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1113-1126.	1.8	59
219	Reversal of anticoagulants: an overview of current developments. <i>Thrombosis and Haemostasis</i> , 2015, 113, 931-942.	1.8	142
220	Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 323-335.	1.0	9

#	ARTICLE	IF	CITATIONS
221	Meta-analysis of dabigatran vs warfarin in patients undergoing catheter ablation for atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 189, 199-203.	0.8	11
222	Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a reappraisal. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S187-S194.	1.9	36
223	New Insights into Nonvitamin K Antagonist Oral Anticoagulants' Reversal of Intracerebral Hemorrhage. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 37, 93-106.	3.0	5
224	Management of Bleeding Associated with New Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 788-801.	1.5	17
225	Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: A dangerous combination?. <i>Clinical Neurology and Neurosurgery</i> , 2015, 136, 73-78.	0.6	36
226	Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Hospital Practice (1995)</i> , 2015, 43, 258-267.	0.5	3
227	Renal cell carcinoma to haemangioblastoma metastasis: A rare manifestation of Von Hippel-Lindau syndrome. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 215-218.	0.8	5
228	Dabigatran-Associated Intracranial Hemorrhage. <i>Neurohospitalist, The</i> , 2015, 5, 234-244.	0.3	12
229	Multimodal assessment of non-specific hemostatic agents for apixaban reversal. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 426-436.	1.9	43
230	Monitoring and reversal strategies for new oral anticoagulants. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 95-103.	0.6	33
231	Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 395-402.	1.0	66
232	Direct Oral Anticoagulants in Frail Older Adults: A Geriatric Perspective. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 389-394.	1.5	23
233	Target-specific oral anticoagulants and the hospitalist. <i>Hospital Practice (1995)</i> , 2015, 43, 1-12.	0.5	1
234	Hemostatic Agents for Bleeding: Recombinant-Activated Factor VII and Beyond. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 342-347.	1.5	7
235	New Oral Anticoagulants: How Do We Use Them Wisely?. <i>Current Cardiology Reports</i> , 2015, 17, 626.	1.3	1
236	Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery. <i>Future Cardiology</i> , 2015, 11, 525-529.	0.5	4
237	Antidotes for Novel Oral Anticoagulants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1736-1745.	1.1	114
238	New oral anticoagulant and antiplatelet agents for neurosurgeons. <i>British Journal of Neurosurgery</i> , 2015, 29, 614-621.	0.4	4

#	ARTICLE	IF	CITATIONS
239	Laboratory Testing in the Era of Direct or Non-Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 208-227.	1.5	95
240	Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. <i>Lancet, The</i> , 2015, 386, 680-690.	6.3	302
241	Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 185, 209-213.	0.8	20
242	Ex vivo reversal of the anticoagulant effects of edoxaban – comments on the study by Halim et al.. <i>Thrombosis Research</i> , 2015, 135, 571.	0.8	0
243	Balancing Anti-thrombotic Efficacy and Bleeding Risk in the Contemporary Management of Venous Thromboembolism. <i>Current Emergency and Hospital Medicine Reports</i> , 2015, 3, 89-99.	0.6	1
244	Global assays and the management of oral anticoagulation. <i>Thrombosis Journal</i> , 2015, 13, 9.	0.9	48
245	Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 309-318.	0.7	3
246	Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 235-242.	1.0	17
247	Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate. <i>Circulation</i> , 2015, 131, 82-90.	1.6	240
248	Efficacy and Safety of Apixaban in the Patients Undergoing the Ablation of Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 155-163.	0.5	48
249	Practical Management of Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1340-1360.	1.2	92
250	Dabigatran for the prevention and treatment of thromboembolic disorders. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 529-540.	0.6	6
251	Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers. <i>Transfusion Medicine Reviews</i> , 2015, 29, 242-249.	0.9	26
252	Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. <i>Critical Care</i> , 2015, 19, 203.	2.5	77
254	The evolving role of dabigatran etexilate in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2053-2072.	0.9	0
255	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	0.7	951
256	The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. <i>Thrombosis Research</i> , 2015, 136, 825-831.	0.8	32
257	Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 297-308.	0.7	6

#	ARTICLE	IF	CITATIONS
258	Risk of major bleeding in different indications for new oral anticoagulants: Insights from a meta-analysis of approved dosages from 50 randomized trials. <i>International Journal of Cardiology</i> , 2015, 179, 279-287.	0.8	67
260	A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 462-472.	1.3	20
261	Outcome following intracranial hemorrhage associated with novel oral anticoagulants. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 212-215.	0.8	15
262	The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants. <i>Current Medical Research and Opinion</i> , 2015, 31, 197-210.	0.9	11
264	Pharmacology and mechanisms of action of new oral anticoagulants. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 10-20.	1.0	33
265	Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. <i>Thrombosis and Haemostasis</i> , 2016, 115, 271-284.	1.8	49
266	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 257-270.	1.8	11
267	Relevant pharmacology for neurovascular procedures. , 0, , 180-201.		0
268	Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians. <i>Emergency Medicine International</i> , 2016, 2016, 1-13.	0.3	22
269	Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy. <i>Case Reports in Critical Care</i> , 2016, 2016, 1-4.	0.2	8
270	Direct Oral Anticoagulants in Emergency Trauma Admissions. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 575-82.	0.6	35
271	Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016. <i>Western Journal of Emergency Medicine</i> , 2016, 17, 264-270.	0.6	36
272	Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1683.	2.0	9
273	Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy. <i>Current Drug Targets</i> , 2016, 17, 954-970.	1.0	47
274	The Use of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Pharmacist's Perspective. <i>Hospital Pharmacy</i> , 2016, 51, 26-34.	0.4	0
275	Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. <i>Vascular Health and Risk Management</i> , 2016, 12, 35.	1.0	80
276	Edoxaban: Impact on routine and specific coagulation assays. <i>Thrombosis and Haemostasis</i> , 2016, 115, 368-381.	1.8	61
277	Hemorrhagic Complications of Rivaroxaban After Eyelid Surgery. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2016, 32, 74.	0.4	7

#	ARTICLE	IF	CITATIONS
278	Reversal of Target-Specific Oral Anticoagulants. , 2016, , 47-54.		0
279	Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysisâ€”A simulation analysis. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 597-608.	1.0	7
280	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016, 220, 417-428.	0.8	9
281	Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation. <i>Medicine (United States)</i> , 2016, 95, e3037.	0.4	18
282	Reversal of direct oral anticoagulants: a practical approach. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 612-619.	0.9	29
283	Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data. <i>International Journal of Cardiology</i> , 2016, 214, 292-298.	0.8	79
284	A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism. <i>American Journal of the Medical Sciences</i> , 2016, 352, 92-106.	0.4	21
285	Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism. <i>Lung</i> , 2016, 194, 605-611.	1.4	15
286	Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, s14-s26.	0.5	15
287	The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. <i>Critical Care</i> , 2016, 20, 100.	2.5	1,014
288	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115.	2.5	40
289	Direct oral anticoagulants. <i>European Journal of Emergency Medicine</i> , 2016, 23, 330-336.	0.5	4
291	New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. <i>Clinical Cardiology</i> , 2016, 39, 739-746.	0.7	15
292	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. <i>Critical Care</i> , 2016, 20, 273.	2.5	19
293	Reversal Agents for the Direct Oral Anticoagulants. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1085-1098.	0.9	8
294	Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients. <i>Transfusion and Apheresis Science</i> , 2016, 55, 249-261.	0.5	4
295	Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation. <i>Journal of Critical Care</i> , 2016, 36, 166-172.	1.0	28
296	Articles That May Change Your Practice: Reversal of Direct Oral Anticoagulant Agents. <i>Air Medical Journal</i> , 2016, 35, 271-272.	0.3	0

#	ARTICLE	IF	CITATIONS
297	Geriatric Resuscitation. <i>Emergency Medicine Clinics of North America</i> , 2016, 34, 453-467.	0.5	8
298	Novel oral anticoagulant management issues for the stroke clinician. <i>International Journal of Stroke</i> , 2016, 11, 759-767.	2.9	4
299	Pathogenesis, Diagnosis, and Treatment of Venous Thromboembolism in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1869-1878.	1.3	20
300	Management of bleeding in patients treated with direct oral anticoagulants. <i>Critical Care</i> , 2016, 20, 249.	2.5	20
301	Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay. <i>British Journal of Anaesthesia</i> , 2016, 117, 583-591.	1.5	23
302	Management of Bleeding Patients. , 2016, , .		3
303	Management of Bleeding With Nonâ€“Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. <i>Circulation</i> , 2016, 134, 248-261.	1.6	98
304	Blood Products. , 2016, , 473-493.		0
305	A Review on the Reversal of the Old and New Anticoagulants. <i>Advanced Emergency Nursing Journal</i> , 2016, 38, 279-294.	0.2	1
306	Pigs Can Be Used as a Large Animal Model for Autologous Fat Grafting. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2016, 32, 73-74.	0.4	6
307	Current Anticoagulation Drugs and Mechanisms of Action. , 2016, , 33-46.		1
308	Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 206-232.	1.0	272
309	The Complex Role of Anticoagulation in Cirrhosis: An Updated Review of Where We Are and Where We Are Going. <i>Digestion</i> , 2016, 93, 149-159.	1.2	51
310	Emergency Reversal of Novel Oral Anticoagulants. <i>JAMA Neurology</i> , 2016, 73, 155.	4.5	2
311	The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage. <i>Neurocritical Care</i> , 2016, 24, 413-419.	1.2	58
312	Target-specific Oral Anticoagulants in the Emergency Department. <i>Journal of Emergency Medicine</i> , 2016, 50, 246-257.	0.3	3
313	Activated prothrombin complex in the management of direct thrombin inhibitor-associated intracerebral haemorrhage. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 415-416.	0.2	2
314	Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 163-170.	1.0	16

#	ARTICLE	IF	CITATIONS
315	Managing Subdural Bleeding Associated With Rivaroxaban. <i>Journal of Pharmacy Practice</i> , 2016, 29, 257-262.	0.5	3
316	Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. <i>Neurocritical Care</i> , 2016, 24, 6-46.	1.2	550
317	Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2016, 30, 823-830.	0.6	11
318	Who, when, and how to reverse non-vitamin K oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 253-272.	1.0	30
319	The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 163-176.	0.6	8
320	Successful hemostasis and reversal of highly elevated PT/INR after dabigatran etexilate use in a patient with acute kidney injury. <i>American Journal of Emergency Medicine</i> , 2016, 34, 758.e5-758.e6.	0.7	6
321	Case Report. <i>Journal of Pharmacy Practice</i> , 2016, 29, 427-430.	0.5	7
322	Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 248-252.	1.0	34
323	Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. <i>Europace</i> , 2016, 18, 955-964.	0.7	62
324	Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke. <i>Current Treatment Options in Neurology</i> , 2017, 19, 1.	0.7	32
325	Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. <i>Thrombosis Research</i> , 2017, 152, 44-48.	0.8	46
327	Clinical implications of reversal agents for direct oral anticoagulants. <i>Future Cardiology</i> , 2017, 13, 153-159.	0.5	7
328	Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review. <i>Annals of Emergency Medicine</i> , 2017, 69, 531-540.	0.3	7
330	Managing the perioperative patient on direct oral anticoagulants. <i>Canadian Journal of Anaesthesia</i> , 2017, 64, 656-672.	0.7	15
331	Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants. <i>Anesthesiology</i> , 2017, 127, 111-120.	1.3	52
332	Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation perspectives. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 769-777.	1.0	10
333	Management of severe perioperative bleeding. <i>European Journal of Anaesthesiology</i> , 2017, 34, 332-395.	0.7	650
334	Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients. <i>Internal and Emergency Medicine</i> , 2017, 12, 425-435.	1.0	6

#	ARTICLE	IF	CITATIONS
335	Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therapeutic Advances in Gastroenterology, 2017, 10, 495-505.	1.4	25
336	Pharmacological management of pulmonary embolism. Expert Opinion on Pharmacotherapy, 2017, 18, 79-93.	0.9	3
337	Bleeding Complications and Management on anticoagulant therapy. Seminars in Thrombosis and Hemostasis, 2017, 43, 886-892.	1.5	10
338	The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. Thrombosis Journal, 2017, 15, 6.	0.9	32
339	Reversal of new oral anticoagulants and personalized medicine. Personalized Medicine, 2017, 14, 5-7.	0.8	0
340	Factor Eight Inhibitor Bypassing Agent (FEIBA) for Reversal of Target-Specific Oral Anticoagulants in Life-Threatening Intracranial Bleeding. Journal of Emergency Medicine, 2017, 52, 731-737.	0.3	20
341	Acquired Bleeding Disorders. Hematology/Oncology Clinics of North America, 2017, 31, 1123-1145.	0.9	13
342	Common Pharmacologic Issues. , 2017, , 405-414.		0
343	Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood, 2017, 130, 1706-1712.	0.6	258
344	Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study. Journal of Thrombosis and Haemostasis, 2017, 15, 2125-2137.	1.9	39
345	Effect of pharmacy management on turnaround time of 4-factor prothrombin complex concentrate. American Journal of Health-System Pharmacy, 2017, 74, S61-S66.	0.5	4
346	Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. Journal of Thrombosis and Thrombolysis, 2017, 44, 527-535.	1.0	9
347	Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants. Expert Review of Hematology, 2017, 10, 833-845.	1.0	1
348	Acute Management of Hemostasis in Patients With Neurological Injury. Transfusion Medicine Reviews, 2017, 31, 236-244.	0.9	7
349	Les complications hémorragiques sous anticoagulants oraux au service des urgences. Journal Europeen Des Urgences Et De Reanimation, 2017, 29, 156-166.	0.1	0
350	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2017, 70, 3042-3067.	1.2	285
353	Prothrombin Complex Concentrates in Pediatric Cardiac Surgery: The Current State and the Future. Annals of Thoracic Surgery, 2017, 104, 1423-1431.	0.7	25
355	Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?. Journal of Emergency Medicine, 2017, 52, 341-347.	0.3	2

#	ARTICLE	IF	CITATIONS
356	Optimal Reversal of Novel Anticoagulants in Trauma. <i>Critical Care Clinics</i> , 2017, 33, 135-152.	1.0	10
357	Coagulopathy of Trauma. <i>Critical Care Clinics</i> , 2017, 33, 101-118.	1.0	60
358	Surgery in the Thrombocytopenic and Coagulopathic Patient. , 2017, , 45-60.		0
359	Measurement and reversal of the direct oral anticoagulants. <i>Blood Reviews</i> , 2017, 31, 77-84.	2.8	133
360	Reversal of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in the Presence of Major Life-Threatening Bleeding. <i>Annals of Emergency Medicine</i> , 2017, 70, 944-945.	0.3	4
361	Reversal of Oral Anticoagulants for Intracerebral Hemorrhage Patients: Best Strategies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 726-736.	0.8	5
362	Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 194-201.	1.0	29
363	Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2017, 117, 269-276.	1.8	32
364	Reversal of direct oral anticoagulants. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 287-292.	1.0	27
365	Managing direct oral anticoagulants for scheduled or emergency surgery: new proposals from the Perioperative Haemostasis Interest Group. <i>Sang Thrombose Vaisseaux</i> , 2017, 29, 106-116.	0.1	1
366	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. <i>Blood Advances</i> , 2017, 1, 1827-1838.	2.5	50
367	Pharmacologic Reversal of Direct Oral Anticoagulants. <i>Critical Care Nursing Quarterly</i> , 2018, 41, 121-128.	0.4	3
369	Pharmacological reversal of the direct oral anticoagulants—A comprehensive review of the literature. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 251-265.	1.0	35
370	What is the Role of Reversal Agents in the Management of Emergency Department Patients with Dabigatran-Associated Hemorrhage?. <i>Journal of Emergency Medicine</i> , 2018, 54, 571-575.	0.3	2
371	Bleeding Disorders and Anticoagulation. , 0, , 19-26.		0
372	Update on the Treatment of Spontaneous Intraparenchymal Hemorrhage: Medical and Interventional Management. <i>Current Treatment Options in Neurology</i> , 2018, 20, 1.	0.7	26
373	Management of the Trauma Patient on Direct Oral Anticoagulants. <i>Current Anesthesiology Reports</i> , 2018, 8, 107-118.	0.9	0
374	Reversal agents for non-vitamin K antagonist oral anticoagulants. <i>Nature Reviews Cardiology</i> , 2018, 15, 273-281.	6.1	116

#	ARTICLE	IF	CITATIONS
375	Current evidence of oral anticoagulant reversal: A systematic review. <i>Thrombosis Research</i> , 2018, 162, 22-31.	0.8	37
376	Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) â€“September 2016. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2018, 37, 391-399.	0.6	36
378	Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 486-495.	1.0	19
379	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 842-851.	1.8	157
380	Major publications in the critical care pharmacotherapy literature: Januaryâ€“December 2016. <i>Journal of Critical Care</i> , 2018, 43, 327-339.	1.0	6
381	Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis. <i>American Journal of Emergency Medicine</i> , 2018, 36, 396-402.	0.7	17
382	Management of Oral Anticoagulant-associated Intracerebral Hemorrhage. <i>Journal of Stroke Medicine</i> , 2018, 1, 114-125.	0.2	0
383	Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes. <i>Journal of Stroke</i> , 2018, 20, 292-301.	1.4	16
384	Calibrated Automated Thrombinography (CAT), a Tool to Identify Patients at Risk of Bleeding during Anticoagulant Therapy: A Systematic Review. <i>TH Open</i> , 2018, 02, e291-e302.	0.7	8
385	Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals. <i>Journal of Critical Care</i> , 2018, 48, 183-190.	1.0	34
386	Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 361-380.	1.0	17
387	Reversing antiâ€“factor Xa agents and the unmet needs in trauma patients. <i>Blood</i> , 2018, 132, 2441-2445.	0.6	10
388	Stroke Revisited: Hemorrhagic Stroke. <i>Stroke Revisited</i> , 2018, , .	0.2	2
389	The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 117S-126S.	0.7	11
390	Management of Antithrombotic-Related Intracerebral Hemorrhage. <i>Stroke Revisited</i> , 2018, , 193-205.	0.2	0
391	Managing Antithrombotic Agents in the Setting of Acute Gastrointestinal Bleeding. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 351-361.	0.6	6
392	Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series. <i>Journal of Medical Case Reports</i> , 2018, 12, 138.	0.4	15
393	Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors. <i>Journal of Intensive Care</i> , 2018, 6, 34.	1.3	57

#	ARTICLE	IF	CITATIONS
394	A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents. <i>Journal of Clinical Medicine</i> , 2018, 7, 29.	1.0	29
395	Rivaroxaban-Associated Intraparenchymal Hemorrhage Managed with 4-Factor Prothrombin Complex Concentrate. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 62-68.	0.6	1
396	Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibitors versus vitamin K antagonists treated with 4-factor prothrombin complex concentrate. <i>Baylor University Medical Center Proceedings</i> , 2018, 31, 153-156.	0.2	20
397	Direct Oral Anticoagulant Agents: Pharmacologic Profile, Indications, Coagulation Monitoring, and Reversal Agents. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 2049-2058.	0.7	50
398	American College of Surgeonsâ€™™ Guidelines for the Perioperative Management of Antithrombotic Medication. <i>Journal of the American College of Surgeons</i> , 2018, 227, 521-536e1.	0.2	89
399	Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. <i>PLoS ONE</i> , 2018, 13, e0195122.	1.1	26
400	Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 278-287.	2.2	61
401	Safety and effectiveness of Factor Eight Inhibitor Bypassing Activity for direct oral anticoagulant-related hemorrhage reversal. <i>American Journal of Emergency Medicine</i> , 2019, 37, 214-219.	0.7	17
402	Retrobulbar haematoma in the era of anticoagulants. <i>Injury</i> , 2019, 50, 1641-1648.	0.7	5
403	Emergency Reversal of Anticoagulation. <i>Western Journal of Emergency Medicine</i> , 2019, 20, 770-783.	0.6	46
404	Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage. <i>Critical Care</i> , 2019, 23, 206.	2.5	47
405	Reversing Direct Oral Anticoagulants in Acute Intracranial Hemorrhage. <i>Critical Care Nurse</i> , 2019, 39, e1-e8.	0.5	1
406	Reversal of Novel Anticoagulants in Emergent Surgery and Trauma: A Comprehensive Review and Proposed Management Algorithm. <i>Current Pharmaceutical Design</i> , 2019, 24, 4540-4553.	0.9	15
407	Idarucizumab, but not procoagulant concentrates, fully restores dabigatranâ€™altered platelet and fibrin components of hemostasis. <i>Transfusion</i> , 2019, 59, 2436-2445.	0.8	8
408	The optimal use of blood components in the management of gastrointestinal bleeding. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 42-43, 101600.	1.0	9
409	Haematological management of major bleeding associated with direct oral anticoagulants â€™ UK experience. <i>British Journal of Haematology</i> , 2019, 185, 514-522.	1.2	15
410	Andexanet Response. <i>Annals of Emergency Medicine</i> , 2019, 74, 724-725.	0.3	0
411	Management of direct factor Xa inhibitorâ€™related major bleeding with prothrombin complex concentrate: a meta-analysis. <i>Blood Advances</i> , 2019, 3, 158-167.	2.5	92

#	ARTICLE	IF	CITATIONS
412	Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. <i>Anesthesiology</i> , 2019, 131, 1153-1165.	1.3	14
413	FDA Approval of Andexanet Alfa Based on a Single-Arm Trial: If There Is a Villain, Who Is It?. <i>Annals of Emergency Medicine</i> , 2019, 74, 725-727.	0.3	0
414	Transfusion Management of Patients Receiving Antithrombotic Therapy. , 2019, , 343-349.		1
415	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section Vê”Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	1.8	28
416	Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage. <i>Stroke</i> , 2019, 50, 529-536.	1.0	22
417	Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding. <i>British Journal of Haematology</i> , 2019, 184, 808-816.	1.2	30
418	Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. <i>Thrombosis Research</i> , 2019, 173, 71-76.	0.8	41
419	Management of Bleeding Associated With Anticoagulation. , 2019, , 91-103.		0
420	Ten things ICU specialists need to know about direct oral anticoagulants (DOACs). <i>Intensive Care Medicine</i> , 2019, 45, 89-92.	3.9	1
421	A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 86-90.	2.3	37
422	A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1203-1208.	1.3	31
423	Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents. <i>Journal of Emergency Medicine</i> , 2020, 58, 217-233.	0.3	22
424	2 venous thromboembolism (VTE) Venous Thromboembolism. , 2020, , .		0
425	Prevention and Treatment of Bleeding with Direct Oral Anticoagulants. <i>Drugs</i> , 2020, 80, 1293-1308.	4.9	6
426	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 594-622.	1.2	187
427	Prothrombin complex concentrates for DOAC-associated bleeding, global coagulation assays, and assessments of clinical hemostasis: How to gauge the impact?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 677-679.	1.0	4
428	Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?. <i>Hamostaseologie</i> , 2020, 40, 364-378.	0.9	8
429	Direct-acting Oral Anticoagulants in Dermatologic Surgery. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2020, 111, 357-363.	0.2	0

#	ARTICLE	IF	CITATIONS
430	Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs). <i>Current Pharmacology Reports</i> , 2020, 6, 241-259.	1.5	10
431	Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?. <i>Thrombosis Journal</i> , 2020, 18, 15.	0.9	5
432	Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 986-998.	1.5	7
433	Anticoagulantes orales directos en cirugía dermatológica. <i>Actas Dermo-sifilográficas</i> , 2020, 111, 357-363.	0.2	4
434	How Do I Reverse Oral and Parenteral Anticoagulants?. <i>Hamostaseologie</i> , 2020, 40, 201-213.	0.9	5
435	What gastroenterologists should know about direct oral anticoagulants. <i>Digestive and Liver Disease</i> , 2020, 52, 1115-1125.	0.4	10
436	Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants. <i>Current Opinion in Critical Care</i> , 2020, 26, 122-128.	1.6	6
437	Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 243-252.	0.5	2
438	Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes. <i>Thrombosis Research</i> , 2020, 195, 21-28.	0.8	8
439	Coagulopathy reversal in intracerebral haemorrhage. <i>Stroke and Vascular Neurology</i> , 2020, 5, 29-33.	1.5	7
440	Management of epistaxis in patients on novel oral anticoagulation therapy. <i>Journal of Laryngology and Otology</i> , 2020, 134, 316-322.	0.4	3
441	Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery. , 2021, , 71-91.		0
442	Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors An In Vitro Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110211.	0.7	2
443	Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage. <i>Pharmacotherapy</i> , 2021, 41, 501-507.	1.2	6
444	Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1137-1150.	1.0	5
446	The AAST prospective observational multicenter study of the initial experience with reversal of direct oral anticoagulants in trauma patients. <i>American Journal of Surgery</i> , 2021, 222, 264-269.	0.9	11
447	Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1091-1102.	1.5	1
448	Activated prothrombin complex concentrate for reversal of oral factor Xa inhibitors at a level 1 trauma center. <i>Thrombosis Research</i> , 2021, 206, 33-35.	0.8	1

#	ARTICLE	IF	CITATIONS
449	Percutaneous Image-Guided Interventions Including Solid Organ Biopsies. , 2021, , 361-375.		0
450	Reversal of Dabigatran-induced Bleeding by Coagulation Factor Concentrates in a Rat-tail Bleeding Model and Lack of Effect on Assays of Coagulation. <i>Anesthesiology</i> , 2014, 120, 1429-1440.	1.3	50
451	Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation. <i>Anesthesiology</i> , 2020, 133, 223-232.	1.3	2
452	Case Scenario: Management of Trauma-induced Coagulopathy in a Severe Blunt Trauma Patient. <i>Anesthesiology</i> , 2013, 119, 191-200.	1.3	17
453	Assessment and management of massive bleeding: coagulation assessment, pharmacologic strategies, and transfusion management. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 522-8.	0.9	7
454	Assessment and management of massive bleeding: coagulation assessment, pharmacologic strategies, and transfusion management. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 522-528.	0.9	19
455	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 117-124.	0.9	12
456	Intracerebral Hemorrhage. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2018, 24, 1603-1622.	0.4	45
457	The Changing Landscape of Trauma Care, Part 1. <i>Emergency Medicine</i> , 2017, 49, 296-305.	0.0	2
458	Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood. <i>PLoS ONE</i> , 2013, 8, e78696.	1.1	126
459	Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants. <i>Arrhythmia and Electrophysiology Review</i> , 2015, 04, 90.	1.3	2
460	Assessment and management of coagulopathy in neurocritical care. <i>Journal of Neurocritical Care</i> , 2019, 12, 9-19.	0.4	14
461	Management of patients who are receiving warfarin or a new oral anticoagulant and require urgent or emergency surgery. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 437-442.	0.3	3
462	Current status of oral anticoagulant reversal strategies: a review. <i>Annals of Translational Medicine</i> , 2019, 7, 411-411.	0.7	25
463	Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. <i>Blood Transfusion</i> , 2016, 14, 23-65.	0.3	78
464	Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis. <i>Orthopedics</i> , 2012, 35, 919-919.	0.5	2
465	Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. <i>Cleveland Clinic Journal of Medicine</i> , 2013, 80, 443-451.	0.6	61
466	Practical issues in the management of novel oral anticoagulants-cardioversion and ablation. <i>Journal of Thoracic Disease</i> , 2015, 7, 115-31.	0.6	8

#	ARTICLE	IF	CITATIONS
467	Reversal Agents in the Era of NOACs: 2017 Update. <i>Journal of Atrial Fibrillation</i> , 2017, 10, 1634.	0.5	9
468	Beyond warfarin: The advent of new oral anticoagulants. <i>Indian Journal of Radiology and Imaging</i> , 2015, 25, 375-379.	0.3	7
469	Update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Cardiovascular Medicine(Switzerland)</i> , 2013, 16, 103-114.	0.1	7
470	Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions. <i>Drugs in Context</i> , 2013, 2013, 1-6.	1.0	5
471	Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events. <i>Thrombosis Update</i> , 2021, 5, 100076.	0.4	1
472	Transfusion Management of Patients Receiving Antithrombotic Therapy. , 2013, , 343-348.		0
473	Anticoagulation for Atrial Fibrillation and Prosthetic Cardiac Valves. , 2013, , 786-799.		0
474	Newer Oral Anticoagulants. , 2014, , 237-248.		0
475	Factor Eight Inhibitor Bypass Activity for Novel Oral Anticoagulant Reversal. <i>Anesthesiology</i> , 2014, 120, 242-243.	1.3	0
476	Oral Anticoagulation. , 2014, , 380-392.		0
477	In Reply. <i>Anesthesiology</i> , 2014, 120, 243-243.	1.3	0
479	Anticoagulation Reversal. , 2015, , 105-123.		0
480	Recent advances in management of anti-coagulation in atrial fibrillation. <i>Journal of Heart and Cardiology</i> , 2015, 2, 1-5.	0.1	0
481	A Tough Pill to Swallow- Spontaneous Retropharyngeal Hematoma: A Rare and Unusual Complication of Rivaroxaban Therapy. <i>Cardiology and Angiology</i> , 2015, 4, 156-159.	0.0	0
482	Managing coagulopathy and thromboprophylaxis in the neurosurgical patient. <i>Advances in Clinical Neuroscience & Rehabilitation: ACNR</i> , 2015, 15, 11-16.	0.1	0
483	Problem-Based Review: Non Vitamin K Antagonist Oral Anticoagulants for the Acute Physician. <i>Acute Medicine</i> , 2015, 14, 83-89.	0.1	3
485	Percutaneous Image-Guided Interventions Including Solid Organ Biopsies. , 2016, , 281-293.		0
487	Oral Anticoagulants. , 2016, , 1-16.		0

#	ARTICLE	IF	CITATIONS
488	Management of Chronically Anticoagulated Patients. , 2016, , 529-542.		0
489	Rescue Strategies to Facilitate Emergency Neurosurgery in Patients on Antiplatelet or Anticoagulant Agents. , 2016, , 243-256.		1
490	Classes of Drugs and Blood Products for Acute Reversal of Anticoagulant Effect. , 2016, , 227-242.		0
491	Management of the Anticoagulated Injured Patient. , 2016, , 115-123.		0
492	Oral Anticoagulants. , 2017, , 1325-1339.		0
493	Pharmacologic Reversal Agents. , 2018, , 109-122.		0
494	Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3274-3281.	0.2	1
495	Administration of high-dose four-factor prothrombin complex concentrate for Xa inhibitor reversal to prevent expansion of intracranial hemorrhage with computed tomography angiography spot sign: a case report. Nosotchu, 2020, 42, 418-422.	0.0	0
496	The prevention and treatment of bleeding associated with direct oral anticoagulants. Klinicheskaia Meditsina, 2020, 96, 491-497.	0.2	0
497	Adjunct Factor Replacement. , 2021, , 443-454.		0
498	Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy. P and T, 2013, 38, 696-701.	1.0	21
499	New oral anticoagulants for atrial fibrillation: are they worth the risk?. P and T, 2014, 39, 54-64.	1.0	10
500	Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Canadian Family Physician, 2014, 60, 997-1001.	0.1	10
501	Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. P and T, 2014, 39, 858-80.	1.0	6
502	How we treat bleeding associated with direct oral anticoagulants. Blood Transfusion, 2016, 14, 465-73.	0.3	8
503	In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates. Blood Transfusion, 2016, 14, 481-6.	0.3	8
504	Use of direct oral anticoagulants in daily practice. American Journal of Blood Research, 2018, 8, 57-72.	0.6	18
505	Intracerebral Hemorrhage (ICH) Approach: Bedside Practical Review. , 2022, , 47-69.		0

#	ARTICLE	IF	CITATIONS
506	Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210788.	0.7	3
510	A new era of anticoagulation. <i>Acta Clinica Belgica</i> , 2012, 67, 394-8.	0.5	0
512	Anticoagulants: dose control methods and inhibitors. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 16, 158-175.	0.2	2
513	Anticoagulation and bleeding in the cancer patient. <i>Supportive Care in Cancer</i> , 2022, 30, 8547-8557.	1.0	3
514	Extensive spontaneous cervical epidural hematoma due to oral anticoagulant (dabigatran) successfully treated with reversal agent idarucizumab alone. , 0, 13, 259.		2
515	Fresh Frozen Plasma in Cases of Acute Upper Gastrointestinal Bleeding Does Not Improve Outcomes. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
516	A Historical Perspective on the Reversal of Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	1.5	3
517	A short review of ciraparantag in perspective of the currently available anticoagulant reversal agents. <i>Drug Discovery Today</i> , 2022, 27, 103332.	3.2	2
519	Direct Oral Anticoagulant Reversal in the Pediatric Emergency Department. <i>Pediatric Emergency Care</i> , 2022, 38, 621-625.	0.5	0
520	DOACs-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 433-452.	1.9	7
521	Reversal agents for current and forthcoming direct oral anticoagulants. <i>European Heart Journal</i> , 2023, 44, 1795-1806.	1.0	14